Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.
Filoviruses, including both Ebola virus (EBOV) and Marburg virus (MARV), can infect humans and other animals, causing hemorrhagic fever with a high mortality rate. Entry of these viruses into the host is mediated by a single filoviral glycoprotein (GP). GP is composed of two subunits: GP1, which is responsible for attachment and binding to receptor(s) on susceptible cells, and GP2, which mediates viral and cell membrane fusion. Although numerous host factors have been implicated in the entry process, the initial attachment receptor(s) has not been well defined. In this report, we demonstrate that exostosin 1 (EXT1), which is involved in biosynthesis of heparan sulfate (HS), plays a role in filovirus entry. Expression knockdown of EXT1 by small interfering RNAs (siRNAs) impairs GP-mediated pseudoviral entry and that of infectious EBOV and MARV in tissue cultured cells. Furthermore, HS, heparin, and other related glycosaminoglycans (GAGs), to different extents, can bind to and block GP-mediated viral entry and that of infectious filoviruses. These results strongly suggest that HS and other related GAGs are attachment receptors that are utilized by filoviruses for entry and infection. These GAGs may have therapeutic potential in treating EBOV- and MARV-infected patients.


OBJECTIVE
Infection by Ebola virus and Marburg virus can cause severe illness in humans, with a high mortality rate, and currently there is no FDA-approved vaccine or therapeutic treatment available. The ongoing 2014 outbreak in West Africa underscores a lack of our understanding in the infection and pathogenesis of these viruses and the urgency of drug discovery and development. In this study, we provide several pieces of evidence that demonstrate that heparan sulfate and other closely related glycosaminoglycans are the molecules that are used by filoviruses for initial attachment. Furthermore, we demonstrate that these glycosaminoglycans can block entry of and infection by filoviruses. Thus, this work provides mechanistic insights on the early step of filoviral infection and suggests a possible therapeutic option for diseases caused by filovirus infection.
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Aileen
A
O'Hearn
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Minxiu
M
Wang
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Han
H
Cheng
U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Calli M
CM
Lear-Rooney
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Katie
K
Koning
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Emily
E
Rumschlag-Booms
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Elizabeth
E
Varhegyi
U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Gene
G
Olinger
Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA lijun@uic.edu.
Lijun
L
Rong
D000818:Animals; D002460:Cell Line; D029043:Ebolavirus / Q000472:pathogenicity / Q000502:physiology; D016563:Filoviridae / Q000472:pathogenicity / Q000502:physiology*; D018702:Filoviridae Infections / Q000209:etiology / Q000821:virology; D055785:Gene Knockdown Techniques; D006025:Glycosaminoglycans / Q000502:physiology*; D057809:HEK293 Cells; D006493:Heparin / Q000502:physiology; D006497:Heparan Sulfate / Q000096:biosynthesis / Q000172:deficiency; D054884:Host-Pathogen Interactions; D006801:Humans; D029024:Marburgvirus / Q000472:pathogenicity / Q000502:physiology; D051379:Mice; D017351:N-Acetylglucosaminyltransferases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D011991:Receptors, Virus / Q000502:physiology; D014764:Viral Proteins / Q000502:physiology; D014774:Virulence; D053586:Virus Internalization; D000099058:Exostosin 1
D006025:Glycosaminoglycans; D006493:Heparin; D006497:Heparan Sulfate; D017351:N-Acetylglucosaminyltransferases; D011991:Receptors, Virus; D014764:Viral Proteins; D000099058:Exostosin 1